Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

NCT04989946 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Degarelix
BIOLOGICAL: pTVG-AR
DRUG: Nivolumab
DRUG: Cemiplimab
DRUG: Fianlimab
DRUG: FLT PET/CT

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]